Advisor Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Advisor Group’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$2K	Sell	2,884 -302	-9%	-$252	﹤0.01%	4991
2019 Q3	$3K	Buy	3,186 +300	+10%	+$311	﹤0.01%	4848
2019 Q2	$3K	Buy	2,886 +302	+12%	+$348	﹤0.01%	4867
2019 Q1	$3K	Sell	2,584 -666	-20%	-$828	﹤0.01%	4849
2018 Q4	$3K	Sell	3,250 -465	-13%	-$712	﹤0.01%	4718
2018 Q3	$8K	Hold	3,715	–	–	﹤0.01%	4385
2018 Q2	$7K	Hold	3,715	–	–	﹤0.01%	4250
2018 Q1	$9K	Sell	3,715 -1,143	-24%	-$2.68K	﹤0.01%	4142
2017 Q4	$9K	Buy	4,858 +1,143	+31%	+$2.5K	﹤0.01%	4142
2017 Q3	$9K	Buy	3,715 +800	+27%	+$1.98K	﹤0.01%	4045
2017 Q2	$8K	Buy	+2,915	New	+$8.14K	﹤0.01%	4042
2016 Q3	–	Sell	-457	Closed	-$1K	–	4546
2016 Q2	$1K	Buy	+457	New	+$1.12K	﹤0.01%	4237

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Advisor Group's LCTX Position: Q4 2019 in Review

Advisor Group reduced its Lineage Cell Therapeutics (LCTX) stake by 9.5% in Q4 2019, selling an estimated $252 and leaving 2,884 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #4991.

Advisor Group first reported a position in LCTX in Q2 2016 and has held it in 12 quarters since. The position peaked at $9K in Q1 2018. 108 funds tracked by Wall St. Rank hold LCTX as of Q4 2019.

Advisor Group held 2,884 shares of Lineage Cell Therapeutics worth $2K as of Q4 2019.
Advisor Group sold 302 Lineage Cell Therapeutics shares in Q4 2019, an estimated $252.
Lineage Cell Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4991 holding.
Advisor Group first reported a position in Lineage Cell Therapeutics in Q2 2016 and has held it in 12 quarters since.
Advisor Group's Lineage Cell Therapeutics position peaked at $9K in Q1 2018.
108 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.